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ABSTRACT (Currently 300/300) 
Background. Dextromethorphan 20mg /quinidine 10mg (DM/Q) was approved to treat 
pseudobulbar affect (PBA) based upon phase 3 trials conducted in participants with 
amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q 
effectiveness, safety and tolerability for PBA following stroke, dementia or traumatic 
brain injury (TBI). Objective. To report results from the TBI cohort of PRISM II, 
including a TBI-specific functional scale. Design. Open-label trial evaluating twice daily 
DM/Q over 90 days. Study participants. Adults (n=120) with a clinical diagnosis of 
PBA secondary to non-penetrating TBI; stable psychiatric medications were allowed. 
Methods. Main Outcome Measurements. Primary endpoint was change in Center for 
Neurologic Study-Lability Scale (CNS-LS) score from baseline to day 90. Secondary 
outcomes included PBA episode count, Clinical and Patient Global Impression of Change 
(CGI-C; PGI-C), Quality of Life-Visual Analog Scale (QOL-VAS), treatment 
satisfaction, Neurobehavioral Functioning Inventory (NFI), Patient Health Questionnaire 
(PHQ-9), and Mini Mental State Examination (MMSE). Results. DM/Q-treated 
participants showed significant mean (SD) reductions in CNS-LS from baseline (day 
30, -5.6 [5.2]; day 90, -8.5 [5.2]; both, P<.001). Compared with baseline, PBA episodes 
were reduced by 61.3% and 78.5% at days 30 and 90 (both, P<.001). At day 90, 78% and 
73% of study participants had “much improved” or “very much improved” on the CGI-C 
and PGI-C. QOL-VAS scores were significantly reduced from baseline (-3.7 [3.3]; 
P<.001). Mean (SD) PHQ-9 scores improved compared to baseline at day 30 (-3.2 [5.3], 
P<.001) and 90 (-5.2 [6.4], P<.001). NFI T-scores were significantly improved (P<.001), 
while MMSE scores were unchanged. Adverse events (AEs) were consistent with the 
known DM/Q safety profile; the most common AE was diarrhea (8.3%). Conclusions. 
DM/Q was well tolerated and significantly reduced PBA episodes in study participants 
with TBI. Changes in CNS-LS and PBA episode count were similar to changes with 
DM/Q in phase 3 trials. 
 
PRISM II TBI Cohort  2 
INTRODUCTION 
Traumatic brain injury (TBI) is associated with a broad range of emotional and 
behavioral disturbances that are often distressing for affected individuals, their family 
members and caregivers.[1] Pseudobulbar affect (PBA) is among the disorders of 
emotion regulation affecting people with TBI and is characterized by sudden, 
uncontrollable outbursts of laughing and/or crying that are independent of mood and out 
of proportion or incongruous to social context.[2,3,4] PBA episodes tend to be 
stereotypical and can last for seconds to several minutes, occur multiple times per day, 
and cause clinically significant distress.[2] PBA episodes can result in embarrassment, 
social isolation, and occupational disability.[3] The pathophysiology of PBA is 
incompletely understood, but brain lesions of various etiologies (inflammatory, ischemic, 
hemorrhagic, or neurodegenerative) involving the corticobulbar tracts, extrapyramidal 
region, or subcortical areas, particularly subcortical white matter, have been associated 
with the uncontrollable laughing or crying episodes of PBA.[5,6] 
 
The diagnosis of PBA is based on patient history and neurological examination, but PBA 
is generally under-recognized due to lack of routine screening, limited awareness of the 
condition, and confusion with other neuropsychiatric conditions.[4,7,8] In the absence of 
specific questioning, patients may fail to describe PBA episodes to their physicians or 
may describe them non-specifically, leading to lack of identification or misattribution to 
mood or other disorders. These factors may play a role in the wide range of estimated 
prevalence rates for PBA in people with TBI. Based on patient interviews, PBA has an 
estimated prevalence of 5 to 30% within the first year following TBI,[9,10,11] but other 
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studies have reported some degree of uncontrollable crying or laughing in up to 48% and 
even 66% with mild TBI as measured using the self-reported Center for Neurologic 
Study–Lability Scale (CNS-LS).[7,12,13] The CNS-LS is a tool to measure laughing and 
crying episode frequency and severity; it was developed and validated using patient 
samples with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).[14,15] A 
CNS-LS score of ≥13 in these studies was found to predict a neurologist diagnosis of 
PBA for 82% of study participants with ALS and 78% with MS, and CNS-LS scores 
correlated well with PBA episode frequency.  
 
Currently, the only drug approved by the US Food and Drug Administration for the 
treatment of PBA is the fixed combination of dextromethorphan (DM) and quinidine (Q) 
(Nuedexta® [DM/Q]; Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA).[16,17] 
Limited evidence also suggests efficacy for some antidepressants; however these are not 
FDA-approved for PBA.[3,18,19,20,21,22,23] 
 
In the United States, the approved DM/Q dose for PBA is 20mg/10 mg twice daily.[16] 
DM is a weak, uncompetitive N-methyl-D-aspartate receptor antagonist, a moderate 
affinity sigma-1 receptor agonist, a serotonin and norepinephrine reuptake inhibitor, and 
an α3β4 neuronal nicotinic receptor antagonist.[24,25,26,27] Due to its rapid metabolism 
to dextrorphan by cytochrome P450 2D6 (CYP2D6), DM typically has poor central 
nervous system bioavailability. However, in the presence of low-dose quinidine (Q), a 
potent CYP2D6 inhibitor, systemic exposure to DM is increased approximately 20-fold, 
without undesirably high concentrations of dextrorphan, resulting in an improved 
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therapeutic profile.[28] DM/Q was approved for the treatment of PBA based on clinical 
trials enrolling study participants with PBA secondary to ALS or MS that showed 
efficacy over placebo or similar doses of DM or Q given alone.[29,30,31] In addition, a 
large (N=553), 1-year safety study enrolled participants with PBA secondary to any 
neurologic condition, but included only a small number of study participants with 
traumatic brain injury (TBI; n=23).[32] 
 
The Pseudobulbar Affect Registry Investigating Symptom Management II (PRISM II) 
trial was conducted to provide expanded DM/Q clinical data for PBA in patient 
populations with Alzheimer’s disease and other dementias, stroke or TBI, three 
neurological conditions commonly associated with PBA. Results from the aggregate 
study and dementia cohort have been reported elsewhere.[33,34] The objective of the 
present article is to specifically report results from the TBI cohort of PRISM II, including 
a functional scale specific to this cohort. 
 
METHODS 
Study Design 
PRISM II was an open-label, 12-week, multicenter trial enrolling adults with PBA 
secondary to dementia, stroke, or TBI and conducted from February 26, 2013 to April 20, 
2015. All study participants received DM/Q 20/10 mg twice daily (once daily in week 1). 
Study visits occurred at baseline and at day 30 and day 90 (or early termination), with a 
telephone consultation at day 60. The study was registered on www.clinicaltrials.gov 
(NCT01799941) and conducted according to Good Clinical Practice and the Declaration 
PRISM II TBI Cohort  5 
of Helsinki at 74 enrolling sites (36 enrolled patients with TBI) across the United States. 
Each site received institutional review board approval.   
 
Study participants 
Study participants were included in the TBI cohort of PRISM II if they were aged ≥18 
years and had a clinical diagnosis of PBA secondary to a non-penetrating TBI of any 
severity. For the purposes of this study, mild TBI was defined as: a loss of consciousness 
(if any) lasting for less than 30 minutes; post-traumatic amnesia lasting less than 24 
hours; or a Glasgow Coma Score of 13 to 15. Moderate TBI was defined as: a loss of 
consciousness lasting for more than 30 minutes but less than 24 hours; post-traumatic 
amnesia lasting from 24 hours to less than 7 days; or a Glasgow Coma Score of 9 to 12. 
Severe TBI was defined as: a loss of consciousness lasting more than 24 hours; post-
traumatic amnesia lasting 7 days or longer; or a Glasgow Coma Score of 8 or less, which 
indicates that the patient is in a coma. 
 
PBA was defined as: involuntary or exaggerated episodes of emotional expression 
(specifically laughing or crying) that that result from a brain disorder; episodes represent 
a change from the person’s usual emotional reactivity and are incongruent or in excess to 
the corresponding mood state or provoking stimulus; and the episodes are not better 
accounted for by another disease state or the direct physiological effect of a substance 
(drug of abuse or medication). A Center for Neurologic Study-Lability Scale (CNS-LS) 
score ≥13 at baseline also was required. Antidepressants and medications for the 
treatment of affective/behavioral or emotional issues secondary to or TBI were allowed 
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provided doses were stable dose for at least 2 months prior to enrollment (6 weeks prior 
to enrollment for memantine and cholinesterase inhibitors).  All other medications were 
allowed to the extent that they were not prohibited in the approved prescribing 
information. Study exclusion criteria were: Mini-Mental State Examination (MMSE) 
score <10, neurologically unstable or stroke within 3 months of screening, history of 
penetrating TBI, severe depressive disorder, active or a history of schizophrenia, 
psychosis, schizoaffective disorder, or bipolar disorder, residence in a mental health 
facility, substance abuse in the 3 years preceding, unstable medical illness, life 
expectation <6 months, contraindication to DM/Q, use of DM/Q within 6 months, or 
participation in an interventional study within 30 days. All study participants (or 
authorized individuals) provided written informed consent. Study participants who were 
unable to complete study measures were required to have a caregiver who could complete 
the study measures on their behalf; a caregiver was defined as a person who spent ≥3 to 4 
days of waking hours with the patient for the week prior to clinic visits (to be 
knowledgeable about PBA episodes). 
 
Outcome Measures 
The primary endpoint was change in CNS-LS score from baseline to day 90 (or final visit 
if early withdrawal). The CNS-LS is a 7-item measure of affective lability of laughing 
and crying [14,15] with scores ranging from 7 to 35 (higher scores indicating higher 
frequency and/or severity of PBA episodes).  
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Secondary measures included the number of PBA episodes (estimated for the 7 days prior 
to each clinic visit), Quality of Life-Visual Analog Scale (QOL-VAS), Clinical and 
Patient Global Impression of Change with respect to PBA (CGI-C and PGI-C, 
respectively),[35] Neurobehavioral Functioning Inventory (NFI), MMSE, Patient Health 
Questionnaire (PHQ-9), and a question assessing treatment satisfaction, and adverse 
events (AEs).  
 
The QOL-VAS is an anchored, continuous line scale that assesses the impact of PBA 
episodes on the participant's global subjective well-being (0 = not at all affected to 10 = 
significantly affected) during the past week. CGI-C and PGI-C[35] are completed by the 
investigator and the participant (or caregiver), respectively, and assess overall change in 
condition and treatment response on a Likert-type scale (1 = very much improved to 7 = 
very much worse).  The NFI is a standardized self-reported rating scale for TBI, 
composed of 76 items organized into 6 independent scales (depression, somatic, 
memory/attention, communication, aggression, and motor).[36] The MMSE[37] 
comprises 11 questions or simple tasks assessing orientation, memory, attention, and 
language to evaluate the patient's cognitive state (scored from 0 to 30). The PHQ-9 is a 9-
item scale that assesses depressive symptoms, scored from 0 to 27 (with higher scores 
indicating greater severity). The treatment satisfaction question is completed by the 
patient (or caregiver) and rates satisfaction with DM/Q treatment as very dissatisfied, 
somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, and very 
satisfied. All scales were completed at day 90; the CNS-LS, PBA episode count and 
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PHQ-9 were also completed at day 30.  AEs occurring any time from enrollment to 30 
days after the last dose of DM/Q were recorded.   
 
Statistical Analysis 
The safety population included all study participants who received at least one dose of 
DM/Q. For the effectiveness analysis, a modified intent-to-treat (mITT) population was 
utilized in which study participants were included if they met all study eligibility criteria, 
received at least one dose of DM/Q, had at least one post-baseline CNS-LS score, and 
were without significant site non-compliance. Unless otherwise specified, statistical tests 
were two-tailed and carried out at the α = 0.05 level of significance; all analyses were 
completed using either SAS v9.2 (SAS Institute Inc, Cary, NC) or Stata v12 (StataCorp, 
College Station, TX). Missing data were not imputed; however, if the patient had a final 
visit, it was included as the day 90 Visit. If there was no final visit, data from the day 30 
visit were not carried forward as the final visit. 
 
The primary analysis tested the null hypothesis that the mean change in CNS-LS score 
from baseline to the day 90 visit was equal to zero; the 95% confidence interval (CI) also 
was calculated to enable a pre-specified descriptive comparison with the CNS-LS change 
observed in the 12-week, phase 3, pivotal registration trial (the STAR trial) conducted in 
study participants with PBA secondary to ALS or MS that led to the US approval of 
DM/Q for PBA.[31]  
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Changes from baseline were analyzed inferentially using one-sample t-tests for rating 
scale measures (CNS-LS, QOL, NFI, MMSE, and PHQ-9). To estimate change in PBA 
episode counts, a mixed-effects Poisson regression model was used, with number of PBA 
episodes in the past seven days as the dependent variable and age, gender, and time (day 
30 and day 90) as fixed effects, while allowing for individual differences in baseline rate 
(a random subject effect). The percentage change in episode rate from baseline to a given 
visit is 1 minus the appropriate time parameter (λ).  
 
An a priori power calculation was performed, based on CNS-LS data from the pivotal 
STAR trial.[31] While caution must be exercised in drawing statistical comparisons 
across trials, the change from baseline values for study participants treated with placebo 
provide a basis for comparison of results for this open-label trial where all study 
participants received DM/Q. The mean (SD) CNS-LS change was –5.7 (5.3) points for 
placebo-treated study participants in the STAR trial. It was determined that a sample size 
of 100 study participants with TBI would provide 80% power to detect a CNS-LS mean 
change of –7.45 points (increase of 1.75 points over assumed true placebo mean change 
of –5.7), or 90% power to detect a CNS-LS mean change of −7.7 points (increase of 2.0 
points over assumed true placebo mean change).  
 
Associations between variables were estimated using the Pearson correlation coefficient 
and the null hypothesis that the true correlation was equal to zero was assessed using 
two-sided tests. AEs were categorized via Medical Dictionary for Regulatory Activities 
(MedDRA version 15.1) coding and reported descriptively.  
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RESULTS 
Participants 
Patient disposition is summarized in Figure 1. Of the 130 study participants screened, 
120 were enrolled and received at least one dose of DM/Q (safety population). A total of 
74 (61.7%) study participants completed the study through day 90. Early discontinuations 
were most commonly due to AEs (11.7%) and loss to follow up (8.3%). A total of 33 
study participants were excluded from the effectiveness analysis set due to any or all: 
lack of post-baseline CNS-LS score (n = 19), failure to meet all inclusion criteria (n = 9), 
or site non-compliance (n = 9). The day 30 mITT analysis population included 87 study 
participants, and 67 study participants with available assessments at day 90.  
 
Baseline demographics and clinical characteristics of the safety population are described 
in Table 1. Mean (SD) patient age was 45.7 (14.1) years, and 95.8% lived at home. 
Based on protocol criteria described above, 48 (40%) study participants were classified as 
having mild TBI, 48 (40%) moderate, and 24 (20%) severe. The most common injury 
mechanism was due to motor vehicle accident (55.8%). A large proportion of study 
participants were taking one or more concomitant psychiatric medications at baseline 
(70.0%), most commonly antidepressants (42.5%), followed by anxiolytics or sedatives 
(38.3%). The mean (SD) CNS-LS score for the mITT population at baseline was 20.5 
(4.3), with mean (SD) PBA episode count for the 7 days prior to baseline of 17.9 (20.3) 
and median of 10 (range: 0, 80; Table 1).  
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Primary Effectiveness Endpoint 
The mean (SD) changes from baseline in CNS-LS score at day 30 and day 90/final visit 
were -5.6 (5.2) and -8.5 (5.2) respectively, which represent significant improvements 
compared to baseline (P<.001, both; Figure 2). The mean (95% CI) improvement of -8.5 
(-9.8, -7.3) from baseline to day 90 in CNS-LS score was consistent with results for the 
same DM/Q dose in the 12-week pivotal STAR trial (mean [95% CI], -8.2 [-9.4, -7.0]) 
and was larger than with placebo (-5.7 [-6.8, -4.7]).[31] The percentage of study 
participants achieving CNS-LS <13 was 38.4% by day 30 and 67.2% by day 90/final 
visit.   
 
Secondary Analyses 
Mean (SD) 7-day PBA episode counts decreased from 17.9 (20.3) at baseline to 6.9 
(12.6) at day 30 (mean change [SD], -11.0 [19.2], P<.0001) and 4.2 (8.0) at day 90 (mean 
change [SD], -15.7 [18.9], P<.0001). Median 7-day episode counts were 10 at baseline, 2 
at day 30, and 1 at day 90. PBA episodes were reduced by 61.3% at day 30 and 78.5% at 
day 90 compared with baseline (P<.001, both). By day 30, 53.7% of study participants 
achieved a ≥75% reduction in PBA episode counts; by day 90, 69.8% of study 
participants achieved a ≥75% reduction in PBA episodes. Complete remission (no 
reported episodes in the week before assessment) was reported by 26.7% at day 30 and 
42.4% at day 90, among study participants with reported episodes in the week before 
baseline. 
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Global impression of change, with respect to PBA, as measured by CGI-C and PGI-C, 
indicated the majority of study participants experienced substantial overall improvement 
(Figure 3). Mean (SD) change in NFI T-score from baseline to day 90/final visit 
improved significantly across all six subscales (Figure 4). The QOL-VAS rating of PBA 
impact on quality of life improved significantly from a baseline mean (SD) of 6.1 (2.6) to 
2.3 (2.8) at day 90/final visit (mean change (SD), -3.7 (3.3); P<.001). At baseline, PHQ-9 
scores were indicative of moderate depression, but improved by day 30 and further 
improved by day 90/final visit to scores indicative of mild depression (Figure 5a). Mean 
(SD) MMSE scores did not change significantly from baseline (27.3 [3.6]) to day 90/final 
visit (27.0 [4.2]; mean change -0.1[3.0] P=.74). A majority of study participants indicated 
they were very satisfied or somewhat satisfied with DM/Q treatment; less than 10% were 
dissatisfied. (Figure 5b). Correlation analysis demonstrated that CNS-LS score reduction 
from baseline to day 90 was significantly correlated with improvements on QOL-VAS, 
PGIC, CGIC, and the PHQ-9, but not with patient satisfaction, weekly PBA episode 
count, and MMSE scores (Table 2). Despite the lack of association of change scores 
between CNS-LS and PBA episode count, absolute CNS-LS score did show significant 
correlation with PBA episode counts at both day 30  and day 90 (Table 2).   
 
Safety 
Among the 120 study participants who received DM/Q (the safety population), 43 
(35.8%) reported at least one AE, including 23 (19.2%) with any AE classified as at least 
possibly related to DM/Q treatment. The most frequently reported AE was diarrhea (n=10 
[8.3%]) followed by dizziness, urinary tract infection, and gastroesophageal reflux 
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disease (each, n=3 [2.5%]). Most AEs were mild or moderate in intensity. Serious AEs 
occurred in 4 (3.3%) study participants, with none considered treatment-related by study 
investigators. These included one study participant with urinary tract infection; one with 
urinary tract infection, prostate infection and sepsis; one study participant with 
myocardial infarction (MI); and one with depression and suicidal ideation. The study 
participant with MI had a family history of cardiac disease on both parental sides (father 
died before age of 50 from cardiac disease), multiple cardiac risk factors, and was also 
receiving taking venlafaxine, gabapentin, estradiol, dextroamphetamine/amphetamine 
and atorvastatin. An EKG obtained during hospitalization revealed ischemia and a non-
ST segment elevation myocardial infarction; however, there was no QT prolongation, and 
the QT interval appeared normal. Cardiac catheterization showed stenosis. Based on the 
above, the investigator assessed the event as not related to DM/Q treatment, and DM/Q 
was restarted after discharge. The patient with suicidal ideation exhibited symptoms of 
wanting to harm himself during the final study visit; although he later retracted the 
statement, he was hospitalized and treatment with DM/Q continued. The patient had a 
history of depression and current social stressors that the investigator considered as the 
likely cause of these symptoms. In total, 14 (11.7%) study participants withdrew from the 
trial due to AEs, most commonly diarrhea (6 [5.0%]), dizziness, nausea, and labile affect 
(2 [1.7%] each).  
 
DISCUSSION 
PRISM II was the first prospectively conducted study to systematically evaluate DM/Q 
effectiveness, including safety and tolerability, for PBA in people with TBI. The trial 
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inclusion and exclusion criteria allowed for a study population that closely resembled 
actual clinical conditions. The main efficacy measure, CNS-LS score, which measures 
the frequency and severity of PBA, improved significantly after both 30 days and 90 days 
of open-label DM/Q treatment, and was consistent with significant reductions in PBA 
episodes. The measured reduction in PBA episodes in this trial appeared clinically 
meaningful, as demonstrated by corresponding improvements in clinician and patient or 
caregiver reported global impression of change with respect to PBA (PGI-C and CGI-C), 
a quality of life assessment (QOL-VAS), and measures of depressive symptoms (PHQ-9) 
and neurobehavioral problems (NFI). Correlation analysis showed that CNS-LS 
improvement was significantly correlated with improvement in each of these secondary 
outcome measures, except for NFI where correlation analysis was not performed. DM/Q 
was generally well tolerated; most AEs were of mild to moderate severity and do not 
represent new or different safety concerns. The purpose of quinidine in DM/Q is to 
inhibit CYP2D6 enzymatic metabolism. As most study participants were receiving 
concomitant neuropsychiatric medications, including some that are metabolized by 
CYP2D6, the safety findings in this population are reassuring in that no new safety 
concerns were identified. Taken together, the use of DM/Q in study participants with TBI 
resulted in effective PBA episode reduction. 
 
The findings in this open-label trial are consistent with three prior randomized, controlled 
trials assessing DM/Q treatment for PBA in study participants with MS or ALS, and with 
results for the stroke and dementia cohorts from this study. These trials, across 5 distinct 
patient populations, demonstrate that DM/Q efficacy is not dependent on the neurologic 
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condition that gives rise to PBA.[29,30,31,33,34] A pre-specified analysis calculated the 
95% CI for mean CNS-LS change at day 90, to allow evaluation relative to CNS-LS 
change in the prior 12-week (84 day), phase 3 pivotal trial. Although treatment 
effectiveness from different trials cannot be directly compared, improvement in mean 
CNS-LS scores in the PRISM II TBI cohort was similar to that seen for the same dose of 
DM/Q in the pivotal trial and greater than the change with placebo in that trial.[31] The 
CNS-LS change in PRISM II also compares favorably to that seen in two earlier 
randomized, controlled trials of DM/Q for PBA that used higher DM/Q doses than this 
trial (range: -7.4 to -7.7).[12,30] The results here are also consistent with PBA 
improvement observed overall in the PRISM II trial, as well as the improvement seen in 
the other individual disease cohorts included in the PRISM II trial [34] and 
dementia[33]). Across the three cohorts, the improvements in CNS-LS and PBA episode 
counts were statistically significant and similar in magnitude. Similarly, results for 
secondary outcomes, including CGI-C and PGI-C, QOL-VAS, and PHQ-9, were 
generally similar across cohorts.[34] The NFI is only administered to persons with TBI in 
this study, and therefore, performance cannot be compared with other cohorts (ie, stroke, 
dementia); however, NFI T-score changes here appear better than those reported 
previously on one study with a similar time frame.[38] Subscales of the NFI likely have 
differences in the maximal performance, or ceiling, that can be achieved. For example, a 
previous analysis identified that motor scores may drop as low as 16 to 8 to represent the 
ceiling improvement, whereas memory/attention scores reach ceiling between 38 to 
19[39] The variance in improvements observed here across subscales seems to align with 
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variance in the reasonable maximal improvement that can be measured on NFI-T 
subscales.  
 
Further, over 40% of study participants here were receiving concomitant antidepressant 
and antiepileptic medications, which may be used off-label to treat PBA. As such, further 
reductions in PBA episodes and symptoms are in addition to any benefit study 
participants may have been receiving from other medications. Taken together, these 
results show a consistent effectiveness of DM/Q for PBA secondary to distinct 
neurological diseases, including ALS, MS, stroke, dementia and TBI. 
 
The limitations of this study are principally the potential subjective bias related to the 
open-label design and use of self-reported measures based on observations by study 
participant, caregiver, or clinician. Although the CNS-LS was validated as a PBA 
measure in studies of people with ALS and MS,[29,30] the scale has not been specifically 
validated in people with TBI. However, the improvements in CNS-LS scores were 
consistent with other outcome measures, including the number of PBA episodes and the 
global measures of change with respect to PBA. As is typical with any clinical trial, 
inclusion and exclusion criteria may have limited the generalizability of the current 
results; however, inclusion criteria in this trial were broader (and exclusion criteria more 
limited) than those traditionally employed in clinical trials, allowing a broader, more 
clinically applicable, range of study participants to enroll. Therefore, generalizability 
should be improved compared with traditional phase 3 trials.  
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CONCLUSIONS 
Open-label DM/Q 20/10mg twice daily resulted in significant improvements in CNS-LS 
scores and significant reduction of PBA episodes and was well tolerated in people with 
PBA secondary to TBI. These findings are consistent with prior well-controlled studies of 
DM/Q for PBA secondary to ALS or MS, and with the results from the other disease 
cohorts of the PRISM II study, and support DM/Q effectiveness for PBA regardless of 
neurologic etiology. 
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Table 1.  Baseline Demographics and Clinical Characteristics, Safety Population 
 Safety Population 
(N=120) 
Age, mean (SD), y 45.7 (14.1) 
Gender, n (%)  
  Male 63 (52.5) 
  Female 57 (47.5) 
Race, n (%)  
  White/Caucasian 98 (81.7) 
  Black/African American 17 (14.2) 
  Native Hawaiian or other Pacific Islander 2 (1.7) 
  Unknown 3 (2.5) 
Ethnicity, n (%)  
  Hispanic/Latino 11 (9.2) 
Place of residence, n (%)  
  Home 115 (95.8) 
  Skilled nursing facility 5 (4.2) 
Injury mechanism, n (%)  
  Fall 29 (24.2) 
  Motor vehicle accident 67 (55.8) 
  Assault 5 (4.2) 
  Struck by/against 8 (6.7) 
  Recreation injury 2 (1.7) 
  Other 9 (7.5) 
TBI severity, n (%)  
  Mild 48 (40) 
  Moderate 48 (40) 
  Severe 24 (20) 
Concomitant medications at baseline  
PRISM II TBI Cohort  23 
  Number of Medications, Mean (SD) 6.5 (4.9) 
  Number of Medications, Median (range) 5.5 (0, 23) 
Psychotropic medications,a n (%)  
  ≥1 Psychotropic Medicationa 84 (70.0) 
  Antiepileptics 35 (29.2) 
  Antipsychotics 17 (14.2) 
  Antidepressants 51 (42.5) 
  Sedatives or anxiolytics 46 (38.3) 
  Any Benzodiazepinesb 37 (30.8) 
  Psychostimulants  19 (15.8) 
  Anti-dementia drugs 10 (8.3) 
Baseline measurements, 
Mean, (SD) 
Effectiveness Analysis 
Population 
n = 87 
  CNS-LSc 20.5 (4.3) 
  PBA episodes/per week   
    Mean (SD) 17.9 (20.3) 
    Median (range)d 10 (0, 80) 
  QOL-VAS 6.1 (2.6) 
  PHQ-9 13.9 (6.5) 
  MMSE 27.3 (3.6) 
aPsychotropic medications included anticonvulsants, antipsychotics, antidepressants, 
sedative/hypnotics, or anxiolytics, and benzodiazepines. 
bBenzodiazepines included benzodiazepines used as sedatives/hypnotics, anxiolytics and  
clonazepam as an anticonvulsant. 
cCNS-LS scores range from 7 to 35, with higher scores indicating increased frequency and 
severity of PBA episodes. 
dMedian reported because data are skewed. 
CNS-LS, Center for Neurologic Study–Lability Scale; MMSE, Mini Mental State Examination; 
PBA, pseudobulbar affect; PHQ-9, Patient Health Questionnaire; QOL-VAS, Quality of Life 
Visual Analog Scale; SD, standard deviation. 
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Table 2. Correlation between CNS-LS and Other Efficacy Outcomes at Day 90 
First Variable Second Variable Pearson 
Correlation 
Observations P-Value 
CNS-LS Patient satisfaction scorea -0.0290 67 0.8157 
CNS-LS Weekly episode rate 0.4381 66 0.0002 
CNS-LS QoL VAS 0.6080 67 <.0001 
CNS-LS PGICb 0.5155 67 <.0001 
CNS-LS CGICb 0.4619 67 <.0001 
CNS-LS MMSE -0.1218 66 0.3298 
CNS-LS PHQ-9 0.6480 67 <.0001 
Weekly episode rate Patient satisfaction scorea -0.1940 66 0.1186 
Weekly episode rate QoL VAS 0.5787 66 <.0001 
Weekly episode rate PGICb 0.4703 66 <.0001 
Weekly episode rate CGICb 0.4791 66 <.0001 
Weekly episode rate MMSE -0.3805 66 0.0016 
Weekly episode rate PHQ-9 0.3534 66 0.0036 
aPatient satisfaction is scored on a Likert-type scale, with higher scores representing greater 
satisfaction (ie, 1, “very dissatisfied” to 5, “very satisfied”). 
bLower scores on the Global Impression of Change are representative of improvement (ie, 1, 
“very much improved” to 7 “very much worse”). 
CGIC, Clinician’s Global Impression of Change; CNS-LS, Center for Neurologic Study–Lability 
Scale; MMSE, Mini Mental State Examination; PHQ-9, Patient Health Questionnaire; PGIC, 
Patient’s/Caregiver’s Global Impression of Change; QOL-VAS, Quality of Life Visual Analog 
Scale. 
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FIGURE LEGENDS 
 
Figure 1. CONSORT Diagram for the PRISM II TBI Cohort 
CNS-LS, Center for Neurologic Study–Lability Scale 
aCategories are not mutually exclusive; a patient may be counted in more than one 
category. 
 
Figure 2. Mean CNS-LS Scores at Baseline, Day 30, and Day 90 in PRISM II TBI 
Cohort (Effectiveness Analysis Set) 
CNS-LS is a patient-reported quantitative measure of the perceived frequency and 
severity of PBA episodes. Scores range from 7 to 35, with higher scores indicating 
increased frequency and severity of PBA episodes. P values were based on the one 
sample t-test and represent comparison with baseline.  
*P<.001 vs. baseline.  
CNS-LS, Center for Neurologic Study–Lability Scale; CI, confidence interval; PBA, 
pseudobulbar affect; SD, standard deviation. 
 
Figure 3. Percent Reduction in Mean PBA Episode Count in PRISM II TBI Cohort 
(Effectiveness Analysis Set) 
Estimated percent change from baseline for PBA episode count was evaluated via a 
mixed-effects Poisson regression model for each time point, based upon patient/caregiver 
estimates of the number of PBA episodes experienced in the 7 days prior to each clinic 
visit.  
*P<.001 vs. baseline. 
PBA, pseudobulbar affect. 
 
Figure 4. 90-day Clinical and Patient Global Impression of Change in PRISM II 
TBI Cohort (Effectiveness Analysis Set)  
CGI-C is a 7-point investigator-rated scale that assess overall treatment response with 
respect to PBA from baseline to day 90/final visit; PGI-C is a 7-point patient/patient’s 
caregiver rated scale that assessed overall treatment response with respect to PBA from 
baseline to day 90/final visit. Percentages use the count of study participants with non-
missing data as the denominator (CGI-C, n=68; PGI-C, n=67) and may not sum to 100.0 
due to rounding.  
CGI-C, Clinical Global Impression of Change; PGI-C, Patient/Caregiver Global 
Impression of Change. 
 
Figure 5. Mean NFI Subscales Scores in PRISM II TBI Cohort (Effectiveness 
Analysis Set) 
NFI T-scores are standardized across six independent subscales; scores range from 1 to 
99 with higher scores indicating greater neurologic disability.  
*P<.001 vs. baseline. 
NFI, Neurobehavioral Functioning Inventory; SD, standard deviation. 
  
Figure 6.  (a) Mean PHQ-9 Score and (b) Patient Treatment Satisfaction in PRISM 
II TBI Cohort (Effectiveness Analysis Set)  
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PHQ-9 is a 9-item scale that assesses depressive symptoms, scored from 0 to 27 with 
higher scores indicating greater severity. Treatment satisfaction was assessed with the 
following question: how satisfied are you with NUEDEXTA as a treatment for your 
pseudobulbar affect?  Results were scored from 1 (very dissatisfied) to 5 (very satisfied).  
*P< .001. 
PHQ-9, Patient Health Questionnaire; SD, standard deviation. 
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